Roman Butler Fullerton & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Roman Butler Fullerton & Co’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,541	Closed	-$1.22M	–	199
2023 Q1	$1.22M	Buy	1,541 +117	+8%	+$88.2K	0.61%	46
2022 Q4	$1.04M	Sell	1,424 -402	-22%	-$297K	0.54%	58
2022 Q3	$1.35M	Buy	+1,826	New	+$1.15M	0.86%	28
2020 Q4	–	Sell	-1,401	Closed	-$784K	–	177
2020 Q3	$784K	Hold	1,401	–	–	0.51%	63
2020 Q2	$874K	Buy	1,401 +318	+29%	+$181K	0.62%	57
2020 Q1	$529K	Buy	+1,083	New	+$447K	0.47%	69
2019 Q1	–	Sell	-1,095	Closed	-$447K	–	182
2018 Q4	$447K	Buy	+1,095	New	+$401K	0.38%	97

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Roman Butler Fullerton & Co's REGN Position: Q2 2023 in Review

Roman Butler Fullerton & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 1,541 shares — an estimated $1.22M sold.

Roman Butler Fullerton & Co first reported a position in REGN in Q4 2018 and held it in 7 quarters. The position peaked at $1.35M in Q3 2022. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

Roman Butler Fullerton & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Roman Butler Fullerton & Co sold 1,541 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $1.22M.
Roman Butler Fullerton & Co first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 7 quarters.
Roman Butler Fullerton & Co's Regeneron Pharmaceuticals position peaked at $1.35M in Q3 2022.
1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2023, filed 25 Jul 2023.